Targeted therapy proves effective against aggressive rare blood cancer
Wednesday, April 24, 2019 - 18:00
in Health & Medicine
Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease.
Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease.